Sanofi's asthma drug Dupixent met all targets in a trial to treat"smoker's lung", potentially adding billions to the French drugmaker's growth prospects, but also underscoring a heavy reliance on its bestseller.
The French group's stock was up 4.5% at 0818 GMT, reaching a seven-month high and far outperforming a 0.5% decline in the STOXX Europe 600 Health Care index. JP Morgan analyst Richard Vosser said the trial update had"blow-out data" in store for investors, and that market consensus for 2027 Dupixent sales of 15.7 billion euros would likely be topped-up by between 1 and 2 billion euros.
The anti-inflammatory drug accounted for 8.3 billion euros, or more than 19% of the French group's overall sales of 43 billion euros, last year. That was a currency-adjusted increase of 44% from a year earlier.The companies said that full efficacy and safety results would be presented later. They added a second late-stage COPD Dupixent trial was ongoing, with the first data read-out expected next year.
_Business I know we all probably might have heard about Bitcoin but don't know how it works, I tried it in a week ago by a woman who recommended me to Thomas__Lawson on Twitter he guides me through the process and I made a lot of money and now I'm recommending her to y'all Thomas__Lawson